100548-49-0

Basic information

• Product Name: 5(R)-5-{(tert-butyldimethylsilyloxy)methyl}pyrrolidin-2-one
• CAS NO: 100548-49-0
• Molecular Formula: C₁₁H₂₃NO₂Si
• Molecular Weight: 229.39132
• EINECS: -0
• Mol File: 100548-49-0.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 5(R)-5-{(tert-butyldimethylsilyloxy)methyl}pyrrolidin-2-one(CAS DataBase Reference)
• NIST Chemistry Reference: 5(R)-5-{(tert-butyldimethylsilyloxy)methyl}pyrrolidin-2-one(100548-49-0)
• EPA Substance Registry System: 5(R)-5-{(tert-butyldimethylsilyloxy)methyl}pyrrolidin-2-one(100548-49-0)

Safety Data

• Hazardous Substances Data: 100548-49-0(Hazardous Substances Data)

Usage

Uses

Used in Organic Synthesis:
5(R)-5-(tert-butyldimethylsilyloxy)methylpyrrolidin-2-one is used as a building block for the synthesis of complex organic molecules. Its unique structure allows for selective reactions and the formation of various functional groups.
Used in Medicinal Chemistry:
In the pharmaceutical industry, 5(R)-5-(tert-butyldimethylsilyloxy)methylpyrrolidin-2-one is used as an intermediate for the synthesis of biologically active molecules and potential drug candidates. Its chiral nature and specific stereochemistry make it a valuable component in the development of enantioselective synthesis processes.
Used as a Protecting Group:
The tert-butyldimethylsilyloxy group in 5(R)-5-(tert-butyldimethylsilyloxy)methylpyrrolidin-2-one is often used as a protecting group for alcohols in organic synthesis. This allows for selective reactions to occur in the presence of other functional groups, facilitating the synthesis of complex molecules with specific desired properties.

Upstream product

• 66673-40-3 (R)-5-hydroxymethylpyrrolidin-2-one 
• 18162-48-6 tert-butyldimethylsilyl chloride 
• 6893-26-1 D-Glutamic acid 
• 13515-99-6 D-glutamic acid dimethyl ester hydrochloride 
• 4042-36-8 D-pyrrolidone-5-carboxylic acid 
• 96914-00-0 C₅H₇NO₂ 
• 64700-65-8 methyl (2R)-pyroglutamate 

Downstream Products

• 128811-31-4 tert-butyl (2R)-2-<<(tert-butyl)dimethylsilyloxy>methyl>-5-oxopyrrolidine-1-carboxylate 
• 356528-12-6 1-(6-Carboxyhexyl)-5β-(3-hydroxy-4-phenyl-1-butenyl)-2-pyrrolidon 
• 540721-64-0 (5R)-1-(4-chlorobutyl)-5-[(1E)-3-hydroxy-4-phenylbut-1-enyl]-pyrrolidin-2-one 
• 540721-68-4 (5R)-1-(4-chlorobutyl)-5-[(1E)-3-oxo-4-phenylbut-1-enyl]pyrrolidin-2-one 
• 540721-57-1 4-{(2R)-2-[(1E)-3-hydroxy-4-phenylbut-1-enyl]-5-oxopyrrolidin-1-yl}butyl thiocyanate 
• 540721-72-0 [(4-{(2R)-2-[(1E)-3-hydroxy-4-phenylbut-1-enyl]-5-oxopyrrolidin-1-yl}butyl)thio]acetonitrile 
• 540721-77-5 methyl [(4-{(2R)-2-[(1E)-3-hydroxy-4-phenylbut-1-enyl]-5-pyrrolidin-1-yl}butyl)thio]acetate 
• 533894-06-3 7-[(R)-2-Oxo-5-((E)-3-oxo-4-phenyl-but-1-enyl)-pyrrolidin-1-yl]-heptanoic acid ethyl ester 
• 540721-70-8 methyl 3-[(4-{(2R)-2-[(1E)-3-hydroxy-4-phenylbut-1-enyl]-5-oxopyrrolidin-1-yl}butyl)thio]propanoate 
• 540731-24-6 7-[(R)-2-((E)-3-Hydroxy-4-methyl-4-phenyl-pent-1-enyl)-5-oxo-pyrrolidin-1-yl]-heptanoic acid ethyl ester 
• 540731-23-5 7-[(R)-2-((E)-4-Methyl-3-oxo-4-phenyl-pent-1-enyl)-5-oxo-pyrrolidin-1-yl]-heptanoic acid ethyl ester 
• 540721-69-5 (5R)-5-[(1E)-3-hydroxy-4-phenylbut-1-enyl]-1-{4-[(triisopropylsilyl)thio]butyl}-pyrrolidin-2-one 

Relevant articles and documents

An expeditious and practical synthetic process for phytosphingosine and tetrahydroxy-LCB from D-glutamic acid

For the asymmetric synthesis of phytosphingosine and 2-amino-1,3,4,5-tetrahydroxyoctadecene, the long chain base (LCB) part of novel cerebrosides, a simple and short synthetic route is described featuring the elabortion of the functionalized homochiral lactam derived from D-glutamic acid as a common structural unit.

Difluoromethylene at the γ-Lactam α-Position Improves 11-Deoxy-8-aza-PGE1 Series EP4 Receptor Binding and Activity: 11-Deoxy-10,10-difluoro-8-aza-PGE1 Analog (KMN-159) as a Potent EP4 Agonist

A series of small-molecule full agonists of the prostaglandin E2 type 4 (EP4) receptor have been generated and evaluated for binding affinity and cellular potency. KMN-80 and its gem-difluoro analog KMN-159 possess high selectivity relative to other prostanoid receptors. Difluoro substitution is positioned alpha to the lactam ring carbonyl and results in KMN-159's fivefold increase in potency versus KMN-80. The two analogs exhibit electronic and conformational variations, including altered nitrogen hybridization and lactam ring puckering, that may drive the observed difluoro-associated increased potency within this four-compound series.

HETEROCYCLYL(PHENYL)METHANOL COMPOUNDS USEFUL IN THE TREATMENT OF HYPERGLYCAEMIA

There is herein provided a compound of formula I or a pharmaceutically acceptable salt thereof, wherein X, R1, R2, R3, ring A, n and y have meanings as provided in the description.

HETEROARYL(HETEROCYCLYL)METHANOL COMPOUNDS USEFUL IN THE TREATMENT OF HYPERGLYCAEMIA

There is herein provided a compound of formula I (I) or a pharmaceutically acceptable salt thereof, wherein the ring comprising Q1 to Q5, R1, m, X1 and ring A have meanings as provided in the description.

INHIBITORS OF APOL1 AND METHODS OF USING SAME

The disclosure provides at least one entity chosen from compounds of formula (I), solid state forms of the same, compositions comprising the same, and methods of using the same, including use in treating focal segmental glomerulosclerosis (FSGS) and/or non-diabetic kidney disease (NDKD).

MODULATORS OF G-PROTEIN COUPLED RECEPTORS

This disclosure features chemical entities (e.g., a compound or a pharmaceutically acceptable salt and/or hydrate and/or prodrug of the compound) that modulate (e.g., agonize or partially agonize or antagonize) glucagon?like peptide?1 receptor ("GLP?1R") and/or the gastric inhibitory polypeptide receptor ("GIPR"). The chemical entities are useful, e.g., for treating a subject (e.g., a human) having a disease, disorder, or condition in which modulation (e.g., agonism, partial agonism or antagonism) of GLP?1R and/or GIPR activities is benficial for the treatment or prevention of the underlying pathology and/or symptoms and/or progression of the disease, disorder, or condition. In some embodiments, the modulation results in an enhancment of (e.g., an increase in) existing levels (e.g., normal or below normal levels) of GLP?1R and/or GIPR activity (e.g., signaling). In some embodiments, the chemical entities described herein further modulate (e.g., attenuate, uncouple) -arrestin signaling relative to what is observed with the native ligand. This disclosure also features compositions as well as other methods of using and making the said chemical entities.

NOVEL FUNCTIONALIZED LACTAMS AS MODULATORS OF THE 5-HYDROXYTRYPTAMINE RECEPTOR 7 AND THEIR METHOD OF USE

Pharmaceutical compositions of the invention comprise functionalized lactam derivatives of formula (I) having a disease-modifying action in the treatment of diseases associated with dysregulation of 5- hydroxytryptamine receptor 7 activity. A is selected

POSITIVE ALLOSTERIC MODULATORS OF MUSCARINIC M2 RECEPTOR

The present application relates to positive allosteric modulators of the muscarinic M2 receptor, especially to novel 7-substituted 1-arylnaphthyridine-3-carboxamides, to processes for preparation thereof, to the use thereof, alone or in combinations, for treatment and/or prevention of diseases, and to the use thereof for production of medicaments for treatment and/or prevention of diseases, in particular for treatment and/or prevention of cardiovascular disorders and/or renal disorders.

LACTAM COMPOUNDS AS EP4 RECEPTOR-SELECTIVE AGONISTS FOR USE IN THE TREATMENT OF EP4-MEDIATED DISEASES AND CONDITIONS

Disclosed herein are compounds of formula (I) wherein L1, L2, L3, L4, R1, R4, R5, R6, and s are as defined in the specification. Compounds of formula (I) are EP4 agonists useful in the treatment of glaucoma, osteoporosis, bone fracture, periodontal bone loss, orthopedic implant, alopecia, neuropathic pain, and related disorders. Pharmaceutical compositions and methods of treating conditions or disorders are also described.

METHODS, SYSTEMS, AND COMPOSITIONS FOR PROMOTING BONE GROWTH

The present invention relates to novel bone compositions for locally delivering a therapeutic agent to the site of a bone defect. Therapeutic agents may promote repair of the bone defect and/or treat conditions or disorders such as pain, inflammation, cancer, and infection. The compositions include calcium phosphate cements and a demineralized bone matrix or a collagen sponge. The compositions are useful for implantation in a patient at the site of a bone defect.